Gemini Therapeutics (Nasdaq: GMTX), a US-based clinical stage ophthalmic company focused on age-related macular degeneration (AMD), has announced a Phase 2a treatment (“ReGAtta” study) and… Read More »Gemini Therapeutics (Cambridge, MA) expect to announce Phase 2a results in H12021 for dry AMD therapy.
A French surgical-robotics company in Montpellier, “AcuSurgical”, has announced a Series A funding of around €5.75 million for an advanced robotic microsurgical platform for the… Read More »“AcuSurgical”, a robotics company for retinal microsurgery based in Montpellier, France, has raised €5.75M funding.
A US biotechnology company, Advernum Biotechnologies Inc., (NASDAQ:ADVM), has announced the enrolment of a Phase 2 study for the treatment of diabetic macular edema (DME),… Read More »Advernum Biotechnologies Inc., (NASDAQ: ADVM) expects to enrol Phase 2 patients for a treatment for DME using the aflibercept gene.
A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the enrolment of a phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10 using a novel therapy for “Sepofarsen” (QR-110)
Genentech (a member of the Roche Group [SIX: RO, ROG; OTCQX: RHHBY]) have announced positive top-line results from two identically designed global Phase III studies,… Read More »Genentech (a subsidiary of Roche) has reported a key non-inferior end-point for faricimab for DME, gearing up for a head-to-head anti-VEGF market
A biotechnology company, Neurogene Inc., has raised $115 million in a second-round financing to be used to accelerate clinical trials. A range of treatments for… Read More »A biotechnology company founded by Neurogene Inc. (NY, USA) has raised $115M to focus on rare Batten disease.
Applied Genetic Technologies Corporation Inc. (Nasdaq: AGTC) has reported positive data from a Phase 1/2 clinical study for 28 X-linked retinitis pigmentosa (XLRP) patients. The company… Read More »Applied Genetic Technologies Corporation (NASDAQ: AGTC; Florida, USA) has reported positive data from a Phase 1/2 study for X-linked retinitis pigmentosa.
Novartis International AG (SIX: NOVN; NYSE: NVS) has announced the acquisition of Vedere Bio, a venture based optogenetics company in Cambridge, Massachusetts. Vedere had developed… Read More »Novartis AG has acquired optogenetics company Vedere Bio for a value up to $280M.
REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company has announced that the first patient has been dosed in the “AAVIATE” trial, a Phase II trial… Read More »Regenxbio Inc. has announced the first patient dosing of Phase II for RGX-314 gene therapy treatment for wet AMD
Novartis have reported two new post-hoc analyses of the Phase III HAWK and HARRIER clinical trials in wet AMD at the EURETINA 2020 virtual congress.… Read More »Novartis reported two new post-hoc analyses of the Phase III HAWK and HARRIER clinical trials at the EURETINA 2020 virtual congress